Avadel Pharmaceuticals’ Lumryz, a once-at-bedtime extended-release sodium oxybate, has received FDA approval for treating cataplexy or excessive daytime sleepiness in patients aged seven years and older with narcolepsy. This expansion in the drug’s indication signifies a significant step forward in pediatric narcolepsy treatment, offering a convenient, single-dose option that aligns with the needs of young patients. The approval is anticipated to drive sales for Avadel, bolstering the company’s position within the narcolepsy treatment market.